Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)
2006; Taylor & Francis; Volume: 24; Issue: 2 Linguagem: Inglês
10.1080/07357900500524397
ISSN1532-4192
AutoresMohamed Hebbar, Christophe Tournigand, Gérard Lledo, May Mabro, Thierry André, Christophe Louvet, Thomas Aparicio, M. Flesch, C. Varette, Aimery de Gramont, Oncology Multidisciplinary Research Group,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
ResumoWe assessed a schedule alternating 4 FOLFOX and 4 FOLFIRI cycles in 39 patients with 5-FU resistant metastatic colorectal cancer. Patients alternatively received 4 FOLFOX-6 cycles (oxaliplatin 100 mg/m2, leucovorin 200 mg/m2 d1 followed by bolus 400 mg/m2 5-FU and by a 46-hour 2,400 mg/m2 5-FU infusion, every 2 weeks), and 4 FOLFIRI cycles (oxaliplatin replaced by irinotecan 180 mg/m2 d1) until progression or limiting toxicity. Eigteen patients achieved an objective response (46.1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety.
Referência(s)